3-phenyl-1-oxa-3,8-diazaspiro[4,5]decan-2-one | 77211-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 3-phenyl-1-oxa-3,8-diazaspiro[4,5]decan-2-one
• 英文别名: 3-Phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
• CAS: 77211-58-6
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.282
• InChiKey: ZBIRMOGNCYIDGT-UHFFFAOYSA-N

物化性质

• 沸点：
  366.6±42.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-氯苯并咪唑 、 3-phenyl-1-oxa-3,8-diazaspiro[4,5]decan-2-one 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 0.67h， 生成 8-(1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
  参考文献：
  名称：

  Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists

  摘要：

  A novel class of benzimidazole NPY Y5 receptor antagonists was prepared exploiting a privileged spirocarbamate moiety. The structure-activity relationship of this series and efforts to achieve a profile suitable for further development and an appropriate pharmacokinetic profile in rat are described. Optimisation led to the identification of the brain penetrant, orally bioavailable Y5 antagonist 9b which significantly inhibited the food intake induced by a Y5 selective agonist with a minimal effective dose of 30 mg/kg po. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.064
• 作为产物：
  描述：

  3-phenyl-8-(carbobenzyloxy)-1-oxa-3,8-diazaspiro<4.5>decan-2-one 在 钯 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、55.15 MPa 条件下， 反应 6.0h， 以affords 2.45 g 3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one的产率得到3-phenyl-1-oxa-3,8-diazaspiro[4,5]decan-2-one
  参考文献：
  名称：

  1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents

  摘要：

  该化合物的分子式为##STR1##其中R.sup.1，R.sup.2和R.sup.3相同或不同，并且是氢，C.sub.1到C.sub.6烷基，C.sub.6到C.sub.14环状芳基或1到6碳原子的烷基基团和6到12碳原子的环状芳基基团，而R.sup.4是选择自公式##STR2##的一组，其中R是C.sub.1到C.sub.8烷基，C.sub.1到C.sub.8烷氧基，卤素，氰基，AlkNHC(O)--或AlkC(O)NH--，而R'是Alk NHC(O)或Alk C(O)NH，其中Alk是C.sub.1到C.sub.6烷基或2-(内环丙烷[3.1.0]己基)乙基。揭示了制备该化合物的方法。该化合物可用于治疗高血压和心脏疾病。

  公开号：

  US04244961A1

文献信息

• SPIRO COMPOUND AND USE THEREOF
  申请人：Taniguchi Takahiko

  公开号：US20100069351A1

  公开（公告）日：2010-03-18

  The present invention aims to provide a novel SCD inhibitor. The present invention relate to SCD inhibitor comprising A compound represented by the formula (I) wherein R is an optionally substituted cyclic group or an optionally substituted carbamoyl group, provided that R is not an optionally substituted 7-pyrido[2,3-d]pyrimidyl group; ring A is an optionally further substituted pyridazine ring; R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 13 and R 14 are each independently a hydrogen atom or a substituent, or R 1 and R 11 in combination, R 2 and R 12 in combination, R 3 and R 13 in combination, or R 4 and R 14 in combination optionally form an oxo group, or R 2 and R 4 in combination optionally form a bond or an alkylene cross-linkage; m and n are each independently an integer of 0 to 2; ring B is an optionally substituted ring, provided that the two atoms constituting ring B, which are adjacent to the spiro carbon atom, are not oxygen atoms at the same time, or a salt thereof, or a prodrug thereof.

  本发明旨在提供一种新型SCD抑制剂。本发明涉及一种包括下式（I）所表示的化合物的SCD抑制剂：其中R是一个可选择取代的环基或可选择取代的氨甲酰基，但R不是一个可选择取代的7-吡啶并[2,3-d]嘧啶基团；环A是一个可选择进一步取代的吡啶并嘧啶环；R1、R2、R3、R4、R11、R12、R13和R14分别独立地是氢原子或取代基，或R1和R11的组合体，R2和R12的组合体，R3和R13的组合体，或R4和R14的组合体可选择形成氧基，或R2和R4的组合体可选择形成键或烷基交联；m和n分别独立地是0到2的整数；环B是一个可选择取代的环，但构成环B的两个与螺碳原子相邻的原子不同时为氧原子，或其盐，或其前药。
• Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones
  作者：Joan M. Caroon、Robin D. Clark、Arthur F. Kluge、Janis T. Nelson、Arthur M. Strosberg、Stefan H. Unger、Anton D. Michel、Roger L. Whiting

  DOI：10.1021/jm00143a012

  日期：1981.11

  Forty-three new 1-oxa-3,8-diazaspiro[4,5]decan-2-ones optionally substituted with 2-(3-indolyl)ethyl, 3-(2-methoxyphenoxy)-2-hydroxypropyl, or 2-(1,4-benzodioxan 2-yl)-2-hydroxyethyl at the 8 position were prepared for screening as antihypertensive agents in the spontaneous hypertensive rat. For the 8-[2-(3-indolyl)ethyl] compounds the most active were those substituted in the 4 position, where activity

  任选被2-（3-吲哚基）乙基，3-（2-甲氧基苯氧基）-2-羟丙基或2-取代的四十三个新的1-oxa-3,8-diazaspiro [4,5] decan-2-one制备在8位的（1，4-苯并二恶烷2-基）-2-羟乙基，以筛选自发性高血压大鼠中的降压药。对于8- [2-（3-吲哚基）乙基]化合物，活性最高的是在4位取代的那些，其中4-乙基化合物（1）的活性最大。8- [3-（2-甲氧基苯氧基）-2-羟丙基]化合物的活性低于其1,4-苯并二恶烷的对应物，后者是作为赤型和苏型非对映异构体的混合物进行测试的。4-乙基-8- [2-（1,4-苯并二恶烷-2-基）-2-羟乙基]-取代的38和（S）-3-甲基-8- [3-（2-甲氧基苯氧基）- 2-羟丙基]-取代的42被设计为混合的α-和β-肾上腺素受体阻滞剂。这两种化合物都降低了血压，但没有提供作为β-肾上腺素能阻滞剂的证据。检验8- [2-（3-吲哚基）乙基]
• [EN] ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS<br/>[FR] DERIVES D'ARYLOXYALKYLAMINE TELS QUE DES LIGANDS DU RECEPTEUR H3
  申请人：GLAXO GROUP LTD

  公开号：WO2004037800A1

  公开（公告）日：2004-05-06

  The present invention relates to novel benzyloxy derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型苄氧基衍生物，其制备方法，含有它们的组合物以及它们在治疗神经系统和精神疾病中的用途。
• Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1<i>H</i>-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors
  作者：Tim Cernak、Nathan J. Gesmundo、Kevin Dykstra、Yang Yu、Zhicai Wu、Zhi-Cai Shi、Petr Vachal、Donald Sperbeck、Shuwen He、Beth Ann Murphy、Lisa Sonatore、Steven Williams、Maria Madeira、Andreas Verras、Maud Reiter、Claire Heechoon Lee、James Cuff、Edward C. Sherer、Jeffrey Kuethe、Stephen Goble、Nicholas Perrotto、Shirly Pinto、Dong-Ming Shen、Ravi Nargund、James Balkovec、Robert J. DeVita、Spencer D. Dreher

  DOI：10.1021/acs.jmedchem.6b01543

  日期：2017.5.11

  Miniaturization and parallel processing play an important role in the evolution of many technologies. We demonstrate the application of miniaturized high-throughput experimentation methods to resolve synthetic chemistry challenges on the frontlines of a lead optimization effort to develop diacylglycerol acyltransferase (DGAT1) inhibitors. Reactions were performed on ∼1 mg scale using glass microvials

  小型化和并行处理在许多技术的发展中起着重要作用。我们展示了微型高通量实验方法的应用，以解决领先的开发二酰基甘油酰基转移酶（DGAT1）抑制剂的最优化工作的前线对合成化学的挑战。使用玻璃微瓶以大约1 mg的规模进行反应，可提供小型化的高通量实验能力，用于研究具有挑战性的S N Ar反应。在这些小型研究中发现的稳健的合成化学条件的可用性使结构-活性关系得以发展，最终导致了可溶性，选择性和有效的DGAT1抑制剂的发现。
• 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
  申请人：Syntex (U.S.A.) Inc.

  公开号：US04244961A1

  公开（公告）日：1981-01-13

  Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are the same or different and are hydrogen, C.sub.1 to C.sub.6 alkyl, C.sub.6 to C.sub.14 carbocyclic aryl or aralkyl of 1 to 6 carbon atoms in the alkyl moiety and 6 to 12 carbon atoms in the carbocyclic aryl moiety and R.sup.4 is selected from the group having the formula ##STR2## where R is C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkoxy, halo, cyano, AlkNHC(O)-- or AlkC(O)NH-- and R' is Alk NHC(O) or Alk C(O)NH where Alk is C.sub.1 to C.sub.6 alkyl or the group 2-(endobicyclo[3.1.0]hexyl)ethyl. Methods for preparing the compounds are disclosed. The compounds are useful for the treatment of hypertension and cardiac disorders.

  该化合物的分子式为##STR1##其中R.sup.1，R.sup.2和R.sup.3相同或不同，并且是氢，C.sub.1到C.sub.6烷基，C.sub.6到C.sub.14环状芳基或1到6碳原子的烷基基团和6到12碳原子的环状芳基基团，而R.sup.4是选择自公式##STR2##的一组，其中R是C.sub.1到C.sub.8烷基，C.sub.1到C.sub.8烷氧基，卤素，氰基，AlkNHC(O)--或AlkC(O)NH--，而R'是Alk NHC(O)或Alk C(O)NH，其中Alk是C.sub.1到C.sub.6烷基或2-(内环丙烷[3.1.0]己基)乙基。揭示了制备该化合物的方法。该化合物可用于治疗高血压和心脏疾病。